Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Hybrid polymer nanoparticles as gene vectors

Descrizione del progetto

Progettare terapie geniche più sicure e intelligenti

La terapia genica ha trasformato la medicina, offrendo una speranza per il trattamento di malattie genetiche e acquisite. Tuttavia, la somministrazione di queste terapie in modo sicuro ed efficace rimane un ostacolo importante. Il progetto HyPlex, finanziato dall’UE, sta affrontando questa sfida sviluppando nanovettori polimerici avanzati. Questi minuscoli vettori trasportano i geni terapeutici alle cellule con maggiore stabilità e minore tossicità. Creando nanogel ibridi di polilisina/poliacrilato e regolando attentamente le loro proprietà chimiche, HyPlex mira a migliorare il modo in cui i geni vengono caricati, veicolati e assorbiti dalle cellule. Il progetto condividerà i risultati con il pubblico, ispirando la prossima generazione di scienziati e incoraggiando le giovani donne a intraprendere una carriera nella ricerca.

Obiettivo

Gene therapy has long been seen as a promising solution to unmet clinical needs and the licencing of gene therapy SARS-CoV-2
vaccines has provided a flavour of the technology’s potential. However, gene therapy still faces significant challenges in clinical and
commercial translation including the need for effective and safe delivery vectors. Polymeric nanoparticles offer great flexibility in
gene vectors design, improved stability and easier scale-up of production compared to lipid nanoparticles but often suffer from
cytotoxicity and underperformance in vivo. The goal of HyPlex is to develop the next generation polymeric nanovectors which can easily be functionalised to further improve delivery efficacy. The project will develop novel chemistry to achieve polylysine/polyacrylate hybrid nanogels. Functionalisation of nanogels will be demonstrated by the introduction of mannose, a common cell binding motive as well as diethylene glycol ethyl ether arylate to optimise the hydrophilic/hydrophobic balance. In an interdisciplinary approach gene loading and cell transfection will be studied up to in vitro level. The project results will be exploited as part of an ongoing commercialisation initiative at RCSI, which will provide the applicant with a unique experience in research translation and commercialisation. The high-level science is complemented by bespoke training activities, which will significantly advance the career opportunities of the applicant. Project results will be communicated to peers as well as the public with specific focus on encouraging female secondary school pupils to take up scientific careers.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2022-PF-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

ROYAL COLLEGE OF SURGEONS IN IRELAND
Contributo netto dell'UE
€ 215 534,40
Indirizzo
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Irlanda
Regione
Ireland Eastern and Midland Dublin
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato